Leerink Partners Maintains Myriad Genetics(MYGN.US) With Hold Rating, Cuts Target Price to $18

Futu NewsJan 22 13:31 · Ratings

Leerink Partners Sticks to Their Hold Rating for Myriad Genetics (MYGN)

TipRanksJan 22 11:35 · Ratings

Myriad Genetics Announces Publication Of Hereditary Cancer Risk Assessment Program Study In Obstetrics & Gynecology

BenzingaJan 21 21:33

Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology

GlobeNewswireJan 21 21:30

Stephens & Co. Reiterates Equal-Weight on Myriad Genetics, Maintains $20 Price Target

BenzingaJan 16 23:28 · Ratings

Myriad Genetics Analyst Ratings

BenzingaJan 16 23:27 · Ratings